drugset / Trial / NCT00505752

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

NCT00505752

Phase 2 Completed 520 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection \[IVF/ICSI\]). This study will compare 3 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f® revised formulation female \[RFF\] Pen) in regards to the number of fertilized oocytes.

Timeline

Start
2007-01
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AS900672-Enriched Protein / enzyme biologic 50 ug Subcutaneous
Subject AS900672-Enriched Protein / enzyme biologic 100 ug Subcutaneous
Subject AS900672-Enriched Protein / enzyme biologic 150 ug Subcutaneous
Subject Gonal-f Protein / enzyme biologic 150 iu Subcutaneous
Background Ovidrel Protein / enzyme biologic 250 ug Subcutaneous

Indications